Innov Clin Neurosci. 2026;23(7–9):32–33. Özlem Totuk, MD, and Sevki Sahin, MD Dr. Totuk is with Sancaktepe Şehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Turkey. Dr. Sahin is
Innov Clin Neurosci. 2026;23(7–9):34–42. Manish Tyagi, MD; Ajay Kumar, MD; Sanjeev Kumar Jain, MD; Sonika Sharma, PhD; and Shehzeen Afag, PhD All authors are with Teerthanker Mahaveer University, Moradabad, India.
Innov Clin Neurosci. 2026;23(7–9):43–45. Çağrı Yenigün, MD, and Çiçek Hocaoğlu, MD Drs. Yenigün and Hocaoğlu are with the Recep Tayyip Erdoğan University Faculty of Medicine, Department of Psychiatry. FUNDING: No
Innov Clin Neurosci. 2026;23(7–9):46–47. Denita Neal, JD Ms. Neal is Senior Risk Manager, Professional Risk Management Services (PRMS). FUNDING: No funding was provided for the preparation of this article. DISCLOSURES:
Dr. Soileau discusses the clinical role of continuous subcutaneous Vyalev (foscarbidopa/foslevodopa) therapy for patients with Parkinson’s disease experiencing motor fluctuations despite optimized oral treatment. He reviews clinical trial data demonstrating
Joe Pierre, MD, summarizes his case report, “You’re Not Crazy”: A Case of New-onset AI-associated Psychosis,” examining the emerging phenomenon of artificial intelligence (AI)-associated psychosis. Using a real-world case of
